Geode Capital Management’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $108M | Buy |
403,151
+330,210
| +453% | +$77.1M | 0.01% | 1156 |
|
|
2026
Q1 | $16.7M | Buy |
72,941
+4,086
| +6% | +$916K | ﹤0.01% | 2091 |
|
|
2025
Q4 | $14.7M | Buy |
68,855
+807
| +1% | +$167K | ﹤0.01% | 2186 |
|
|
2025
Q3 | $13.5M | Buy |
68,048
+7,244
| +12% | +$1.35M | ﹤0.01% | 2228 |
|
|
2025
Q2 | $10.5M | Buy |
60,804
+2,953
| +5% | +$481K | ﹤0.01% | 2338 |
|
|
2025
Q1 | $9.02M | Buy |
57,851
+774
| +1% | +$111K | ﹤0.01% | 2355 |
|
|
2024
Q4 | $7.86M | Buy |
57,077
+629
| +1% | +$82.7K | ﹤0.01% | 2509 |
|
|
2024
Q3 | $8.43M | Sell |
56,448
-1,338
| -2% | -$181K | ﹤0.01% | 2476 |
|
|
2024
Q2 | $7.88M | Buy |
57,786
+1,684
| +3% | +$229K | ﹤0.01% | 2473 |
|
|
2024
Q1 | $8.48M | Buy |
56,102
+1,012
| +2% | +$144K | ﹤0.01% | 2419 |
|
|
2023
Q4 | $6.94M | Buy |
55,090
+535
| +1% | +$53.3K | ﹤0.01% | 2534 |
|
|
2023
Q3 | $5.11M | Buy |
54,555
+990
| +2% | +$92.6K | ﹤0.01% | 2629 |
|
|
2023
Q2 | $4.78M | Buy |
53,565
+1,832
| +4% | +$159K | ﹤0.01% | 2705 |
|
|
2023
Q1 | $5.55M | Buy |
51,733
+541
| +1% | +$61.9K | ﹤0.01% | 2591 |
|
|
2022
Q4 | $6.25M | Buy |
51,192
+6
| +0% | +$697 | ﹤0.01% | 2534 |
|
|
2022
Q3 | $5.29M | Buy |
51,186
+1,490
| +3% | +$141K | ﹤0.01% | 2644 |
|
|
2022
Q2 | $4.62M | Buy |
49,696
+1,846
| +4% | +$174K | ﹤0.01% | 2738 |
|
|
2022
Q1 | $5.62M | Buy |
47,850
+977
| +2% | +$113K | ﹤0.01% | 2728 |
|
|
2021
Q4 | $6.3M | Buy |
46,873
+2,077
| +5% | +$309K | ﹤0.01% | 2758 |
|
|
2021
Q3 | $7.14M | Buy |
44,796
+519
| +1% | +$71K | ﹤0.01% | 2705 |
|
|
2021
Q2 | $5.82M | Buy |
44,277
+814
| +2% | +$108K | ﹤0.01% | 2812 |
|
|
2021
Q1 | $5.6M | Buy |
43,463
+599
| +1% | +$91K | ﹤0.01% | 2735 |
|
|
2020
Q4 | $7.15M | Buy |
42,864
+3,668
| +9% | +$607K | ﹤0.01% | 2391 |
|
|
2020
Q3 | $6.05M | Buy |
39,196
+923
| +2% | +$133K | ﹤0.01% | 2281 |
|
|
2020
Q2 | $5.66M | Buy |
38,273
+841
| +2% | +$115K | ﹤0.01% | 2264 |
|
|
2020
Q1 | $4.21M | Buy |
37,432
+4,785
| +15% | +$622K | ﹤0.01% | 2240 |
|
|
2019
Q4 | $4.54M | Buy |
32,647
+132
| +0.4% | +$14.7K | ﹤0.01% | 2516 |
|
|
2019
Q3 | $3.13M | Sell |
32,515
-176
| -0.5% | -$19.6K | ﹤0.01% | 2665 |
|
|
2019
Q2 | $3.76M | Buy |
32,691
+1,618
| +5% | +$194K | ﹤0.01% | 2577 |
|
|
2019
Q1 | $3.66M | Buy |
31,073
+330
| +1% | +$28.9K | ﹤0.01% | 2506 |
|
|
2018
Q4 | $1.93M | Buy |
30,743
+3,459
| +13% | +$217K | ﹤0.01% | 2797 |
|
|
2018
Q3 | $1.93M | Buy |
27,284
+242
| +0.9% | +$16.7K | ﹤0.01% | 2904 |
|
|
2018
Q2 | $1.8M | Buy |
27,042
+6,267
| +30% | +$412K | ﹤0.01% | 2914 |
|
|
2018
Q1 | $1.36M | Buy |
20,775
+385
| +2% | +$21.6K | ﹤0.01% | 2975 |
|
|
2017
Q4 | $816K | Buy |
20,390
+418
| +2% | +$15.2K | ﹤0.01% | 3178 |
|
|
2017
Q3 | $723K | Buy |
19,972
+286
| +1% | +$8.21K | ﹤0.01% | 3232 |
|
|
2017
Q2 | $546K | Buy |
19,686
+4,869
| +33% | +$129K | ﹤0.01% | 3325 |
|
|
2017
Q1 | $414K | Buy |
+14,817
| New | +$374K | ﹤0.01% | 3377 |
|
Other funds holding ASND
RCM
ACA
JT
Geode Capital Management's ASND Position: Q2 2026 in Review
Geode Capital Management increased its Ascendis Pharma A/S (ASND) stake by 453% in Q2 2026, buying an estimated $77.1M and bringing the position to 403,151 shares worth $108M. The position accounts for 0.01% of the portfolio, ranked #1156.
Geode Capital Management first reported a position in ASND in Q1 2017 and has held it in 38 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Geode Capital Management held 403,151 shares of Ascendis Pharma A/S worth $108M as of Q2 2026.
- Geode Capital Management bought 330,210 Ascendis Pharma A/S shares in Q2 2026, an estimated $77.1M.
- Ascendis Pharma A/S made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #1156 holding.
- Geode Capital Management first reported a position in Ascendis Pharma A/S in Q1 2017 and has held it in 38 quarters since.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.